| Immunomodulation in sepsis: state of the art and future perspective. | |
| | |
MedLine Citation:
|
PMID: 21174562 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Despite advances in supportive care of critically ill patients, sepsis remains an important cause of death worldwide. More than 750,000 individuals develop severe sepsis in North America annually, with a mortality rate varying between 35 and 50%. Over recent years, numerous efforts have been committed to understanding the pathophysiology of septic syndrome, as well as attempts to intervene in the inflammatory cascade with the aim of altering the outcome of the syndrome and to improve survival. Not all of these attempts have been successful. Issued guidelines by the International Sepsis Forum have incorporated only the use of corticosteroids, tight glycemic control and the use of recombinant activated protein C as recommendations for the management of the septic patient along with the initial resuscitation and infection-site control measures. These strategies along, with novel attempts of immunomodulation, are thoroughly reviewed in this article. |
| | |
Authors:
|
Anastasia Antonopoulou; Evangelos J Giamarellos-Bourboulis |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Immunotherapy Volume: 3 ISSN: 1750-7448 ISO Abbreviation: Immunotherapy Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2010-12-22 Completed Date: 2011-04-11 Revised Date: 2011-04-28 |
Medline Journal Info:
|
Nlm Unique ID: 101485158 Medline TA: Immunotherapy Country: England |
Other Details:
|
Languages: eng Pagination: 117-28 Citation Subset: IM |
Affiliation:
|
4th Department of Internal Medicine, ATTIKON University General Hospital, 1 Rimini St., 12462 Athens, Greece. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenal Cortex Hormones
/
therapeutic use Anti-Inflammatory Agents / therapeutic use* Clinical Trials as Topic Glycoproteins / therapeutic use* Humans Immunomodulation* Protein C / genetics, therapeutic use Recombinant Proteins / therapeutic use Sepsis / immunology*, mortality, physiopathology, therapy* Thymosin / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Adrenal Cortex Hormones; 0/Anti-Inflammatory Agents; 0/Glycoproteins; 0/Protein C; 0/Recombinant Proteins; 61512-21-8/Thymosin; 80449-32-7/urinastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Role of tyrosine kinase inhibitors in tumor immunology.
Next Document: Physical therapists' perceptions of providing services to adults with childhood-onset neuromotor dis...